3-甲基-1H-吡唑-5-羧肼 | 40535-14-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-甲基-1H-吡唑-5-羧肼
• 中文别名: 3-甲基-1H-吡唑-5-羧酸肼；5-甲基-2-H-吡唑-3-羧肼；5-甲基-1-H-吡唑-3-羧肼
• 英文名称: 5-methylpyrazole-3-carbohydrazide
• 英文别名: 5-methyl-1H-pyrazole-3-carbohydrazide；5-methyl-1H-pyrazole-3-carboxylic acid hydrazide
• CAS: 40535-14-6
• 化学式: C₅H₈N₄O
• mdl: MFCD00068101
• 分子量: 140.145
• InChiKey: FWNHUZOBVQZERU-UHFFFAOYSA-N

物化性质

• 熔点：
  157 °C
• 密度：
  1.337±0.06 g/cm3(Predicted)
• 溶解度：
  9.4 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  83.8
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 储存条件：
  2-8℃

SDS

Name:	3-Methyl-1h-pyrazole-5-carbohydrazide 97% Material Safety Data Sheet
Synonym:	3-Methylpyrazole-5-carboxic acid hydrazid
CAS:	40535-14-6

Section 1 - Chemical Product MSDS Name:3-Methyl-1h-pyrazole-5-carbohydrazide 97% Material Safety Data Sheet
Synonym:3-Methylpyrazole-5-carboxic acid hydrazid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
40535-14-6	3-Methyl-1H-pyrazole-5-carbohydrazide	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 40535-14-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white crystalline solid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 156 - 158 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H8N4O
Molecular Weight: 140

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 40535-14-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Methyl-1H-pyrazole-5-carbohydrazide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 40535-14-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 40535-14-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 40535-14-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲基-1H-吡唑-5-羧肼 在 hydrazine hydrate monohydrate 作用下， 反应 5.0h， 生成 5-甲基-1H-吡唑-3-羧酸
  参考文献：
  名称：

  5-甲基吡唑-3-羧酸的铜(II)和钴(II)配合物：合成、X射线晶体学、热分析和体外抗菌活性

  摘要：

  摘要 [Cu(mpca)2(H2O)]·3H2O (1) [Cu(mpca)2]·的固态分离和表征证明了5-甲基吡唑-3-羧酸(Hmpca)的配位行为。 H2O (2) 和 [Co(mpca)2(H2O)2] (3)。新化合物的特征在于 X 射线晶体学、热重分析和 DFT 研究。通过循环伏安分析来检查配合物的氧化还原特性。化合物对八种细菌（大肠杆菌、粪肠球菌、枯草芽孢杆菌、肺炎克雷伯菌、普通变形杆菌、金黄色葡萄球菌、铜绿假单胞菌和伤寒沙门氏菌）和两种真菌（黄曲霉和念珠菌）的抗菌和抗真菌活性进行了筛选琼脂井扩散法。与配体相比，金属配合物对所有细菌和真菌的抑制效果更好。复合物的高亲脂性解释了对微生物的良好抑制作用。在报道的复合物中，3 是一种出色的抗真菌剂和比标准氟康唑更好的抗生素。结构和活性关系表明复合物具有足够的 Jahn-Teller 畸变和高 logP 值，穿过微生物的细胞膜，造成细胞间损伤。图形概要

  DOI：

  10.1080/00958972.2018.1520984
• 作为产物：
  描述：

  5-甲基-1H-吡唑-3-羧酸 在 硫酸 、 一水合肼 作用下， 反应 2.0h， 生成 3-甲基-1H-吡唑-5-羧肼
  参考文献：
  名称：

  Musante; Mugnaini, Gazzetta Chimica Italiana, 1947, vol. 77, p. 182,193

  摘要：

  DOI：

文献信息

• [EN] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES<br/>[FR] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES
  申请人：BAYER AG

  公开号：WO2021028382A1

  公开（公告）日：2021-02-18

  The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）中R1、R2、R3、R4、R5、R6、R7和R8如所定义的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病有关的情况，作为唯一药剂或与其他活性成分组合使用。
• [EN] SUBSTITUTED AZA-BRIDGED BICYCLICS FOR CARDIOVASCULAR AND CNS DISEASE<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS À PONT AZA POUR MALADIE CARDIOVASCULAIRE ET DU SYSTÈME NERVEUX CENTRAL
  申请人：DECODE GENETICS EHF

  公开号：WO2010059836A1

  公开（公告）日：2010-05-27

  The invention relates to substituted imidazopyridines, pyrazolotriazinones, triazolopyridines, pyrazolopyridines and pyrazolopyrimidines that are useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I (I) or II (II) in which Cy1 and Cy2 are carbocycles or heterocycles.

  这项发明涉及用于治疗中风、心肌梗死和心血管炎症状况的取代咪唑吡啶、吡唑三唑酮、三唑吡啶、吡唑吡啶和吡唑吡嘧啶化合物，以及包含这些化合物的药物组合物，以及在哺乳动物中治疗中风、心肌梗死和心血管炎症状况的方法。这些化合物具有一般式I（I）或II（II），其中Cy1和Cy2是碳环或杂环。
• Pyrazole–oxadiazole conjugates: synthesis, antiproliferative activity and inhibition of tubulin polymerization
  作者：Ahmed Kamal、Anver Basha Shaik、Sowjanya Polepalli、Vangala Santosh Reddy、G. Bharath Kumar、Soma Gupta、K. V. S. Rama Krishna、Ananthamurthy Nagabhushana、Rakesh K. Mishra、Nishant Jain

  DOI：10.1039/c4ob01152j

  日期：——

  4-(methylenedioxy) substituent on their A rings. Among these conjugates, 11a, 11d and 11f manifest potent cytotoxicity with IC50 values ranging from 1.5 μM to 11.2 μM and inhibit tubulin polymerization with IC50 values of 1.3 μM, 3.9 μM and 2.4 μM respectively. The cell cycle assay showed that treatment with these conjugates results in accumulation of cells in the G2/M phase and disrupts the microtubule network

  合成了许多吡唑-恶二唑偶联物，并评估了它们在各种人类癌细胞系中作为抗增殖剂的能力。这些缀合物由彼此紧密连接的吡唑和恶二唑支架组成，没有任何间隔子作为两个结构类别。I类具有三甲氧基取代基，II类具有在其A环上的3,4-（亚甲基二氧基）取代基。在这些结合物中，11a，11d和11f表现出强的细胞毒性，IC 50值为1.5μM至11.2μM，并抑制微管蛋白的IC 50聚合分别为1.3μM，3.9μM和2.4μM。细胞周期分析表明，用这些缀合物处理会导致细胞在G2 / M期积累，并破坏微管网络。斑马鱼胚胎的阐明表明，缀合物导致发育缺陷。分子对接模拟确定了这些有效结合物在微管蛋白秋水仙碱位点的结合模式。
• Synthesis and antioxidant activity evaluation of a syringic hydrazones family
  作者：Nadji Belkheiri、Benaissa Bouguerne、Florence Bedos-Belval、Hubert Duran、Corinne Bernis、Robert Salvayre、Anne Nègre-Salvayre、Michel Baltas

  DOI：10.1016/j.ejmech.2010.03.031

  日期：2010.7

  A novel series of hydrazones derived from syringaldehyde and their antioxidant properties have been explored. Several employed methods such as scavenging effect on 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical and 2,2′-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS•+) radical cation expressed as Trolox equivalent antioxidant capacity (TEAC), inhibition of superoxide anion (O2•−) generation and

  已经探索了一系列从丁香醛衍生的新型hydr及其抗氧化性能。几种采用的方法，例如对2,2-二苯基-1-吡啶并肼基（DPPH）和2,2'-叠氮基双（3-乙基苯并噻唑啉-6-磺酸）（ABTS • +）自由基阳离子的清除作用表示为Trolox等效抗氧化剂容量（TEAC），抑制超氧阴离子（O 2 •−）和人类细胞介导的低密度脂蛋白氧化（由TBARS的形成来监测）的产生表现出了有效的抗氧化特性。还通过测量降低被氧化的LDL攻击的细胞中蛋白质羰基含量的能力来评估羰基清除剂的功效。在这份报告中，我们讨论了hydr的合成及其双重生物学作用，抗氧化剂和羰基清除剂，以进一步在动脉粥样硬化中应用。
• An orthogonal ferromagnetically coupled tetracopper(<scp>ii</scp>) 2 × 2 homoleptic grid supported by µ-O₄bridges and its DFT study
  作者：Somnath Roy、Tarak Nath Mandal、Anil Kumar Barik、Sachindranath Pal、Ray J. Butcher、Mohamed Salah El Fallah、Javier Tercero、Susanta Kumar Kar

  DOI：10.1039/b617587b

  日期：——

  pyrazole based ditopic ligand (PzOAP), prepared by the reaction between 5-methylpyrazole-3-carbohydrazide and methyl ester of imino picolinic acid, reacts with Cu(NO3)2.6H2O to form a self-assembled, ferromagnetically coupled, alkoxide bridged tetranuclear homoleptic Cu(II) square grid-complex [Cu4(PzOAP)4(NO3)2] (NO3)2.4H2O (1) with a central Cu4[micro-O4] core, involving four ligand molecules. In

  由吡咯-3-氨基甲酰肼与亚氨基吡啶甲酸的甲酯反应制得的吡唑基对位配体（PzOAP）与Cu（NO3）2.6H2O反应形成自组装，铁磁耦合，烷氧基桥接的四核均质的Cu（II）方格网状复合物[Cu4（PzOAP）4（NO3）2]（NO3）2.4H2O（1），具有中心Cu4 [micro-O4]核心，涉及四个配体分子。在Cu4 [micro-O4]芯中，在四个铜中心中，两个铜中心是五配位的，其余​​两个是六配位的。在六配位的每种情况下，第六位被硝酸根离子占据。配合物1已经在结构和磁性上进行了表征。尽管Cu-O-Cu桥角太大（138-141度），而Cu-Cu距离很短（4.043-4.131 A），适用于在网格内传播预期的反铁磁交换相互作用，但分子内铁磁交换（J = 5.38 cm（-1））存在，S = 4/2磁性基态。从几乎垂直于金属中心之间的桥接连接（d（x2-y2）），这种铁磁相互作用非常明显。